Ugur Sahin, head of the German BioNTech vaccine manufacturer, said on January 11 that the new crown vaccine against Omicron jointly developed by the pharmaceutical company and Pfizer will enter clinical research at the end of January this year (2022). stage. "If we can get official approval, we estimate that a Covid-19 vaccine against Omicron could be on the market in March," Shaheen said. So far, the European Medicines Agency (EMA) has not said whether it is necessary to use a new crown vaccine specifically for Omicron.
Pfizer CEO Albert Bourla also said recently that he does not know whether the new vaccine will be put into use, and Pfizer will produce Shadow Making the new vaccine at its own risk. Meanwhile, the Walter Reed Army Institute of Research in the United States is developing a universal Covid-19 vaccine that could protect people from all variants of SARS-CoV-2. Last December (2021), the institute just concluded the first phase of clinical trials on the vaccine with positive results. Unlike vaccines already in use, the Walter Reed Army Institute's SpFN vaccine can attach different spike proteins to 24 surfaces of ferritin nanoparticles.
This means that a single nanoparticle can accommodate not only various SARS-CoV-2 mutant strains, but also the spikes of various other common coronaviruses. arrow_forward_ios了解更多 Powered by GliaStudio 72 adults between the ages of 18 and 55 participated in a Phase 1 clinical trial of the new vaccine. Testers received two doses of the vaccine at 180-day intervals, or three doses at 28- and 180-day intervals. Testers who received three doses of the vaccine were divided into two groups, one of which received a higher third dose than the other. This is done to test the tolerability of the vaccine and to collect data on the extent of antibody responses at different doses.